Glucose variability: a new parameter of diabetes compensation?

Authors: Martin Haluzík
Authors‘ workplace: III. interní klinika 1. LF UK a VFN, Praha, Česká republika
Published in: Forum Diab 2012; 1(2-3): 71-76
Category: Topic


Glycated hemoglobin and other parameters currently used to assess diabetes compensation do not necessarily reflect a complete real picture of diabetes control in all patients. Patients with profound oscillations of blood glucose from hypo- to hyperglycemic values with relatively satisfactory glycated hemoglobin and random fasting glucose represent a typical example of this fact. Most of experimental and some of clinical studies have suggested that major blood glucose oscillations may through the stimulation of oxidative stress and other mechanisms contribute to the development of diabetic complications and increased cardiovascular risk independently of diabetes compensation measured by glycated hemoglobin. A parameter that mathematically defines glucose oscillations within a defined time frame is commonly referred to as glucose variability. The aim of this review is to discuss cu­rrent knowledge with respect to relationship of glucose variability and long-term diabetic complications, prediction of hypoglycemia and other clinically relevant parameters. Several studies have suggested that glucose variability may become another important parameter reflecting the quality of diabetes compensation and the risk of long-term complications. It is possible that reduction of glucose variability could additionally decrease the risk of complications independently of diabetes compensation measured by glycated hemoglobin values. Further prospective interventional studies are necessary to confirm this interesting prospect.

Key words:
diabetes compensation – glucose variability – complications – hypoglycemia


1. O´Rahilly S. Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ 1997; 314(7085): 955–959

2. Grundy SM. Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient? Am J Med 2007; 120(9 Suppl 1): S3-S8; discussion S9.

3. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes care 2003; 26(5): 1589–1596.

4. Mazze RS, Strock E, Wesley D et al. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther 2008; 10(3): 149–159.

5. Škrha J. et al. Diabetologie. 1. vyd. Praha: Galén 2009.

6. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107(9): 1058–1070.

7. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocrine reviews 2010; 31(2): 171–182.

8. Picconi F, Di Flaviani A, Malandrucco I et al. Impact of glycemic variability on cardiovascular outcomes beyond glycated hemoglobin. Evidence and clinical perspectives. Nutr Metab Cardiovasc Dis 2012; 22(9): 691–696.

9. Quagliaro L, Piconi L, Assaloni R et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003; 52(11): 2795–804.

10. Piconi L, Quagliaro L, Assaloni R et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev 2006; 22(3): 198–203.

11. Takeuchi A, Throckmorton DC, Brogden AP et al. Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. Am J Physiol 1995; 268(1 Pt 2): F13-F19.

12. Jones SC, Saunders HJ, Qi W, Pollock CA. Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetologia 1999; 42(9): 1113–1119.

13. Horvath EM, Benko R, Kiss L et al. Rapid ‚glycaemic swings‘ induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia 2009; 52(5): 952–961.

14. [autor neuveden] The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44(8): 968–983.

15. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes care 2006; 29(7): 1486–1490.

16. Lachin JM, Genuth S, Nathan DM et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes 2008; 57(4): 995–1001.

17. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes care 2008; 31(11): 2198–2202.

18. Ceriello A, Esposito K, Piconi L et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57(5): 1349–1354.

19. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295(14): 1681–7.

20. Wentholt IM, Kulik W, Michels RP et al. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 2008; 51(1): 183–190.

21. Siegelaar SE, Barwari T, Kulik W et al. No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol 2011; 5(1): 86–92.

22. Siegelaar SE, Kulik W, Lenthe H van et al. A randomized clinical trial comparing the effect of basal insulin and inhaled mealtime insulin on glucose variability and oxidative stress. Diabetes Obes Metab 2009; 11(7): 709–714.

23. Bragd J, Adamson U, Backlund LB et al. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab 2008; 34(6 Pt 1): 612–616.

24. Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B, Lou-Arnal LM. Fasting plasma glucose variability as a risk factor of retinopathy in Type 2 diabetic patients. J Diabetes Complications 2003; 17(2): 78–81.

25. Raz I, Wilson PW, Strojek K et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009; 32(3): 381–386.

26. Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 2008; 36(11): 3008–3013.

27. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345(19): 1359–1367.

28. Hirshberg E, Larsen G, Van Duker H. Alterations in glucose homeostasis in the pediatric intensive care unit: Hyperglycemia and glucose variability are associated with increased mortality and morbidity. Pediatr Crit Care Med 2008; 9(4): 361–366.

29. Kovatchev BP, Cox DJ, Farhy LS et al. Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J Clin Endocrinol Metab 2000; 85(11): 4287–4292.

30. Murata GH, Hoffman RM, Shah JH et al. A probabilistic model for predicting hypoglycemia in type 2 diabetes mellitus: The Diabetes Outcomes in Veterans Study (DOVES). Arch Intern Med 2004; 164(13): 1445–1450.

31. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007; 50(12): 2553–2561.

32. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007; 9(5): 648–659.

33. Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab 2011; 13(8): 677–684.

34. Irace C, Fiorentino R, Carallo C et al. Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes. Diabetes Technol Ther 2011; 13(12): 1261–1263.

35. McCall AL, Cox DJ, Brodows R et al. Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine. Diabetes Technol Ther 2009; 11(6): 339–344.

36. Lin SD, Wang JS, Hsu SR et al. The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complications 2011; 25(5): 332–338.

37. Marfella R, Barbieri M, Grella R et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010; 24(2): 79–83.

38. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition. Diabetes care 2012. Dostupné z WWW (DOI): http:/doi:10.2337/dc12–0199.

Diabetology Endocrinology Internal medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account